Clinical trials of WR-2721 with radiation therapy. 1982

A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman

The radioprotector with clinical potential, S-2-(3 aminopropylamino)-ethylphosphorothioic acid (WR-2721) is undergoing two Phase I trials. The objectives of these trials are 1) to determine the maximum tolerated dose (MTD) of WR-2721 in a single dose and 2) to determine the highest dose of WR-2721 that can be tolerated daily in the greatest number of fractions per week. A total of 65 patients have been treated. The single maximum tolerated dose has not yet been reached, though 740 mg/m2 is well tolerated. A single dose of 910 mg/m2 has been successfully administered to one patient. The multiple dose MTD is at an early stage with patients currently receiving 170 mg/m2 four times a week. Among the toxicities noted in both trials are hypotension, hypertension, emesis and somnolence. In addition, in the multiple dose trial there have been three patients who have had allergic reactions including one which was life-threatening. Phase II studies are planned and will begin when the maximum tolerated dose is established from each Phase I trial.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009946 Organothiophosphorus Compounds Compounds containing carbon-phosphorus bonds in which the phosphorus component is also bonded to one or more sulfur atoms. Many of these compounds function as CHOLINERGIC AGENTS and as INSECTICIDES. Compounds, Organothiophosphorus
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004999 Amifostine A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. Ethiofos,Gammaphos,APAETP,Amifostine Anhydrous,Amifostine Disodium Salt,Amifostine Monohydrate,Amifostine Monohydrochloride,Amifostine Trihydrate,Aminopropyl Aminoethylthiophosphate,Aminopropylaminoethylthiophosphate,Aminopropylaminoethylthiophosphoric Acid,Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester), trihydrate,Ethiofos Anhydrous,Ethyol,NSC-296961,S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid,WR-2721,YM-08310,NSC 296961,NSC296961,WR 2721,WR2721,YM 08310,YM08310
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
May 1989, International journal of radiation oncology, biology, physics,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
January 1980, Cancer clinical trials,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
February 1984, Radiation research,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
January 1988, Pharmacology & therapeutics,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
January 1990, Cancer investigation,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
June 1976, Radiation research,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
September 1984, International journal of radiation oncology, biology, physics,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
September 1984, International journal of radiation oncology, biology, physics,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
January 1988, Pharmacology & therapeutics,
A L Blumberg, and D F Nelson, and M Gramkowski, and D Glover, and J H Glick, and J M Yuhas, and M M Kligerman
August 1986, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!